A COVID-19 vaccine candidate under development by China’s CanSino Biologics is moving forward in development after the company published data supporting patient safety.

The U.S. Food and Drug Administration approved Marlborough, Massachusetts-based Sunovion Pharmaceuticals’ Kynmobi (apomorphine HCl) sublingual film for Parkinson’s disease.

The malaria drug hydroxychloroquine – which U.S. President Donald Trump says he has been taking – is tied to increased risk of death in COVID-19 patients, according to a study published in the medical journal Lancet.

BioSpace reviews some of the more interesting scientific studies recently published, including a Phase II clinical trial out of Hong Kong that found a three drug-antiviral cocktail significantly decreased median time to a negative SARS-CoV-2 test compared to controls.

A brief roundup of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

A look at which parts of the body the novel coronavirus infects and how SARS-CoV-2 is transmitted from person to person.

Toronto-based NoNO Inc. announced results from the pivotal Phase III ESCAPE-NA1 trial of intravenous nerinetide in patients with acute ischemic stroke who were chosen to undergo endovascular thrombectomy.

Abbott’s ARCHITECT STAT High Sensitivity Troponin-I blood test received clearance from the U.S. Food and Drug Administration to help identify heart attacks several hours sooner than standard troponin tests and help improve diagnosis in women.

OncoCyte Corporation, a developer of novel tests for the early diagnosis and management of lung cancer, announced a definitive agreement to acquire Razor Genomics.

Teva Pharmaceutical Industries Ltd.’s anti-CGRP drug fremanezumab hit the target reducing monthly migraine days in a late-stage study.